

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-15. (Canceled)

~~16~~¹. (Previously Presented) A method for treating rheumatoid arthritis in a human subject, said method comprising administering to said subject a therapeutically effective amount of an IL-12 antagonist that binds with IL-12, wherein said antagonist is chosen from a group consisting of an antibody immunoreactive with IL-12 and an antibody fragment immunoreactive with IL-12.

17. (Canceled)

~~18~~². (Previously Presented) The method of claim ~~16~~¹, wherein said antagonist is administered in combination with a pharmaceutically acceptable carrier.

~~19~~³. (Previously Presented) The method of claim ~~16~~¹, wherein said antagonist is an antibody immunoreactive with IL-12.

~~20~~⁴. (Previously Presented) The method of claim ~~16~~¹, wherein said antagonist is an antibody fragment is immunoreactive with IL-12.

~~21~~⁵. (Previously Presented) The method of claim ~~16~~¹, wherein the antibody is a monoclonal antibody.

~~22~~⁶. (Previously Presented) The method of claim ~~16~~¹, wherein the antibody binds to a heterodimer comprised of a 40 kD subunit and an 35 kD subunit of IL-12.

23. (Canceled)

24. (Canceled)

⁷
~~25.~~ (Previously Presented) The method of claim ~~16~~¹, wherein said antagonist is administered in a dose of from about 0.05 to about 25 mg/kg.

⁸
~~26.~~ (Previously Presented) The method of claim ~~16~~¹, wherein said antagonist is administered in a dose of from about 0.2 to about 2 mg/kg.

⁹
~~27.~~ (Previously Presented) The method of claim ~~16~~¹, wherein said antagonist is administered intravenously.

¹⁰
~~28.~~ (Previously Presented) The method of claim ~~16~~¹, wherein said antagonist is administered subcutaneously.

¹¹
~~29.~~ (Previously Presented) The method of claim ~~16~~¹, wherein said antagonist is administered cutaneously.

¹²
~~30.~~ (Previously Presented) The method of claim ~~16~~¹, wherein said antagonist is administered in combination with other therapies for autoimmune conditions.

¹³
~~31.~~ (Previously Presented) The method of claim ~~30~~¹², wherein said therapies comprise steroidal or other anti-inflammatory therapies.

32-43. (Canceled)

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com